Patent SG-11201805941W-A (SG)
Title: Tgfbeta 2 antibodies
Inventor: IBEBUNJO CHIKWENDU
IPC: C07K16/22
Filed: 2017-02-17
Abstract: met G.o1 1 iOa Yo966 .150 con& Imp . o MOR13434 • • 4Ent fate A •,,r.Z.11,9436. • (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/141208 Al 24 August 2017 (24.08.2017) WIPO I PCT (51) International Patent Classification: C07K 16/22 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/IB2017/050917 (22) International Filing Date: 17 February 2017 (17.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/296,282 17 February 2016 (17.02.2016) US (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4053 Basel (CH). (72) Inventors: IBEBUNJO, Chikwendu; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). JACOBI, Carsten; Novartis Pharma AG, Postfach, Novartis Insti- tutes for Biomed. Research, 4002 Basel (CH). MEYER, Angelika; Novartis Pharma AG, Postfach, Novartis Insti- tutes for Biomed. Research, 4002 Basel (CH). SCHAADT, Eveline; MORPHOSYS AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). TRENDELENBURG, Anne-Ul- rike; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). VLADIMIROVNA MITINA, Olga; Morphosys AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4053 (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: — with international search report (Art. 21(3)) [Continued on next page] = (54) Title: TGFBETA 2 ANTIBODIES Figure 3: Biologic activity and isoform-specificity by RGA activity (MOR13436) RGA:t9FDP40y t TGF4 it9A.PFOR:nti'GF-az 111111111111110111011111111111010111110 01011111011101011111110111111111110111111 W O 20 17 / 141208 Al o MOiR 1 S43 e CAT 15re g WS.V.2231 1 0.0691 0.0 -ipg 1 01196 Iii RsAloromap TGF-p! RIGA TaF-01 (57) : This invention is in the field of anti-transforming growth factor beta 2 (TGF-132) antibodies. In particular, the inven - tion provides human monoclonal antibodies that bind the human TGF-132 isoform preferentially over the human TGF-131 or TGF-133 isoforms. WO 2017/141208 Al 1#110HO1101DION01013010111101101011HOMOVOIMIE — with sequence listing part of description (Rule 5.2(a))